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  ABSTRACT	  Bladder	  cancer	  is	  a	  serious	  health	  concern	  among	  the	  older	  population,	  as	  it	  is	  responsible	  for	  thousands	  of	  deaths	  annually	  in	  the	  United	  States.	  Patients	  that	  are	  diagnosed	  with	  muscle-­‐invasive	  disease	  have	  a	  5-­‐year	  survival	  rate	  of	  only	  20	  percent.	  Additionally,	  muscle-­‐invasive	  disease	  has	  a	  high	  metastatic	  potential;	  half	  of	  all	  patients	  develop	  metastatic	  disease	  within	  3	  years.	  Patients	  with	  muscle-­‐invasive	  disease	  are	  presented	  with	  few	  treatment	  options	  aside	  from	  surgery.	  The	  current	  standard	  of	  care	  is	  a	  chemotherapeutic	  combination	  therapy	  of	  cisplatin	  and	  gemcitabine.	  This	  therapy	  is	  highly	  toxic,	  and	  due	  to	  the	  high	  instance	  of	  co-­‐morbidities	  in	  these	  patients,	  approximately	  half	  are	  unfit	  for	  therapy.	  An	  alternative	  combination	  of	  carboplatin	  plus	  gemcitabine	  allows	  for	  the	  inclusion	  of	  more	  patients,	  but	  is	  an	  inferior	  therapy.	  Development	  of	  an	  alternative	  treatment	  option	  is	  necessary.	  	  Previous	  studies	  in	  the	  Foreman	  lab	  have	  shown	  a	  synergistic	  decrease	  in	  bladder	  cancer	  cell	  proliferation	  when	  the	  natural	  alkaloid	  emetine	  is	  combined	  with	  cisplatin	  in	  vitro.	  Here,	  we	  expanded	  these	  studies	  to	  demonstrate	  that	  the	  addition	  of	  emetine	  to	  both	  the	  cisplatin-­‐gemcitabine	  as	  well	  as	  carboplatin-­‐gemcitabine	  standard	  of	  care	  regimens	  resulted	  in	  an	  additive	  decrease	  in	  bladder	  cancer	  cell	  proliferation.	  Moreover,	  the	  addition	  of	  low	  dose	  emetine	  allows	  for	  up	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to	  a	  10-­‐fold	  decrease	  in	  effective	  dose	  of	  cisplatin	  or	  carboplatin.	  Treatment	  with	  this	  triple	  therapy	  appears	  to	  be	  inducing	  growth	  arrest	  in	  the	  cancer	  cells.	  	  	  Hypoxia	  Inducible	  Factors	  (HIFs)	  are	  upregulated	  in	  response	  to	  low	  oxygen	  conditions,	  and	  regulate	  a	  wide	  range	  of	  genes	  responsible	  for	  giving	  tumor	  cells	  a	  selective	  advantage.	  HIF-­‐α	  overexpression	  in	  bladder	  cancer	  corresponds	  to	  a	  poorer	  prognosis.	  This,	  as	  well	  as	  the	  concise	  regulation	  of	  HIFs,	  makes	  them	  an	  attractive	  target	  for	  anti-­‐cancer	  therapy.	  	  HIF-­‐1α	  and	  HIF-­‐2α	  are	  aberrantly	  upregulated	  under	  normoxia	  conditions	  in	  the	  invasive	  bladder	  cancer	  cell	  lines	  UMUC3,	  HT1376,	  and	  T24.	  Emetine	  is	  a	  know	  protein	  synthesis	  inhibitor	  at	  the	  micromolar	  level,	  but	  less	  is	  known	  about	  its	  actions	  at	  lower	  concentrations.	  We	  demonstrate	  here	  that	  low,	  nanomolar	  concentrations	  of	  emetine	  act	  to	  preferentially	  downregulate	  levels	  of	  HIF-­‐1α	  and	  HIF-­‐2α.	  Emetine	  appears	  to	  be	  acting	  via	  decreased	  HIF-­‐1α	  protein	  synthesis.	  	  We	  hypothesize	  that	  emetine	  is	  acting	  in	  a	  similar	  manner	  on	  HIF-­‐2α,	  but	  further	  work	  is	  necessary	  to	  confirm.	  This	  regulation	  of	  hypoxia	  signaling	  may	  act	  to	  decrease	  the	  cell’s	  selective	  advantage	  and	  proliferative	  potential.
1	  	  
CHAPTER	  1	  	  
INTRODUCTION	  HYPOXIA	  Oxygen	  homeostasis	  is	  a	  tightly	  regulated	  process	  in	  mammals.	  Hypoxia	  is	  a	  reduction	  in	  the	  normal	  level	  of	  tissue	  oxygen	  tension	  and	  occurs	  when	  oxygen	  demand	  exceeds	  supply.	  	  1	  	  Hypoxia	  is	  an	  important	  factor	  in	  diseases	  such	  as	  vascular	  disease,	  pulmonary	  disease,	  and	  cancer.	  Tumors	  become	  hypoxic	  because	  they	  outgrow	  their	  blood	  supply,	  or	  their	  vasculature	  is	  aberrant	  or	  has	  poor	  blood	  flow.	  Cells	  will	  die	  if	  hypoxia	  is	  prolonged,	  but	  cancer	  cells	  have	  adapted	  ways	  to	  survive	  even	  in	  a	  hypoxic	  environment,	  leading	  to	  a	  more	  aggressive	  phenotype.	  	  2	  	  Hypoxia	  Inducible	  Factors	  (HIFs)	  are	  transcription	  factors	  that	  upregulate	  many	  genes	  to	  promote	  angiogenesis	  and	  cell	  survival	  in	  response	  to	  low	  oxygen	  conditions.	  	  3,4	  	  HIFs	  regulate	  up	  to	  2	  percent	  of	  the	  genome,	  including	  genes	  involved	  in	  angiogenesis,	  erythropoeisis,	  cell	  proliferation,	  glucose	  metabolism,	  migration,	  invasion,	  and	  cell	  survival.	  	  1,5	  	  The	  expression	  of	  many	  response	  genes,	  including	  VEGF	  (vascular	  endothelial	  growth	  factor)	  occur	  in	  almost	  all	  cell	  types,	  while	  the	  expression	  of	  the	  majority	  of	  genes	  regulated	  by	  HIFs	  are	  cell-­‐type	  specific.	  6,7	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Figure	  1.	  Structure	  of	  HIF-­α 	  and	  HIF-­β  (Adapted	  from	  Bracken	  et	  al.,	  2003)	  	  HIF-­‐α	  and	  HIF-­‐β	  are	  basic-­‐helix-­‐loop-­‐helix/per-­‐ARNT-­‐sim	  (bHLH/PAS)	  proteins	  that	  share	  a	  high	  degree	  of	  homology,	  including	  the	  N-­‐terminal	  transactivating	  domain	  (N-­‐TAD)	  and	  the	  C-­‐terminal	  transactivating	  domain	  (C-­‐TAD).	  HIF-­‐α	  differs	  from	  HIF-­‐β	  in	  that	  it	  contains	  an	  oxygen	  dependent	  degradation	  domain	  (ODD),	  which	  is	  responsible	  for	  regulating	  its	  stability	  in	  response	  to	  oxygen	  levels.	  	  
	  





Figure	  2.	  Structure	  of	  HIF-­α 	  isoforms.	  (Adapted	  from	  Bracken	  et.	  al.,	  2003)	  	  HIF-­‐1,	  2,	  &	  3-­‐α	  share	  a	  high	  degree	  of	  homology,	  including	  the	  basic-­‐helix-­‐loop-­‐helix	  (bHLH)	  and	  per-­‐ARNT-­‐sim	  (PAS)	  domains,	  the	  N-­‐terminal	  transactivating	  domain	  (N-­‐TAD)	  and	  the	  oxygen	  dependent	  degradation	  domain	  (ODD).	  HIF-­‐3α	  lacks	  the	  C-­‐terminal	  transactivating	  domain	  (C-­‐TAD)	  present	  in	  both	  HIF-­‐1α	  and	  HIF-­‐2α.	  	  
HIF-­α 	  Stability	  and	  Regulation	  Hypoxia	  has	  no	  significant	  effect	  on	  levels	  of	  HIF-­‐1α	  mRNA,	  but	  drastically	  increases	  the	  abundance	  of	  HIF-­‐α	  protein.	  	  15	  	  Under	  normal	  oxygen	  conditions,	  PHD’s	  use	  O2	  and	  2-­‐oxoglutarate	  in	  the	  cell	  to	  hydroxylate	  HIF	  at	  Proline	  402	  &	  Proline	  564.	  	  5,16	  	  (Figure	  3)	  The	  E3	  ubiquitin	  ligase,	  von	  Hippel-­‐Lindau	  (VHL)	  	  recognizes	  this	  modification	  and	  polyubiquitylates	  HIF-­‐α,	  targeting	  it	  for	  degradation	  via	  the	  proteasome.	  	  5	  	  A	  second	  posttranslational	  modification	  that	  stabilizes	  HIFs	  interaction	  with	  VHL	  is	  the	  acetylation	  of	  Lys532	  in	  the	  ODD	  by	  ARD1	  acetyl	  transferase.	  	  17	  	  FIN,	  or	  factor	  inhibiting	  HIF,	  further	  modifies	  HIF-­‐α	  in	  the	  presence	  of	  O2,	  2-­‐oxaloglutarate,	  and	  iron	  by	  hydroxylating	  an	  asparagine	  residue	  in	  the	  C-­‐TAD,	  preventing	  the	  interaction	  of	  HIF	  with	  co-­‐activators,	  reducing	  
5	  
	  













Figure	  4:	  Growth	  factor	  initiated	  upregulation	  of	  HIF-­α 	  proteins.	  	  Growth	  factors	  stimulate	  HIF-­‐α	  transcription	  via	  activation	  of	  both	  the	  mitogen-­‐activated	  protein	  kinase	  (MAPK)	  and	  phosphatidylinositol	  3-­‐kinase	  (PI3)	  pathways.	  	  
	  
HIF	  and	  Cancer	  Hypoxia	  and	  HIFs	  are	  implicated	  in	  many	  diseases	  including	  cancer.	  	  1	  	  As	  HIFs	  upregulate	  genes	  involved	  in	  angiogenesis,	  glycolysis,	  and	  other	  pro-­‐survival	  genes,	  their	  presence	  gives	  the	  tumor	  cells	  a	  selective	  advantage.	  1	  	  This,	  plus	  the	  tight	  regulation	  of	  HIF	  activity	  makes	  it	  an	  attractive	  therapeutic	  target.	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The	  overexpression	  of	  HIF-­‐1α	  and/or	  HIF-­‐2α	  proteins	  have	  been	  implicated	  in	  various	  tumors,	  including	  invasive	  bladder	  cancer,	  brain	  tumors,	  breast	  cancer,	  cervical	  cancer,	  non-­‐small-­‐cell	  lung	  cancer,	  non-­‐Hodgkin’s	  lymphoma,	  oropharyngeal	  cancer,	  pancreatic	  cancer,	  colon,	  skin,	  gastric,	  prostate,	  and	  renal	  clear	  cell	  carcinomas.	  	  1,34	  	  The	  importance	  of	  HIF	  in	  tumorigenesis	  is	  highlighted	  in	  clear	  cell	  renal	  carcinoma,	  where	  a	  majority	  of	  tumors	  overexpress	  HIF-­‐α	  due	  to	  VHL	  mutations.	  35,36	  	  Enforced	  HIF-­‐α	  overexpression	  in	  bladder	  cancer	  cells	  increases	  their	  tumorigenic	  potential-­‐causing	  them	  to	  grow	  more	  rapidly	  and	  form	  larger	  tumors	  in	  
vivo.	  37-­‐39	  	  In	  patient	  samples,	  HIF-­‐α	  expression	  correlates	  with	  poor	  prognosis	  in	  bladder	  cancer.	  40,41	  	  Specifically,	  HIF-­‐2α	  protein	  expression	  in	  surgical	  specimens	  of	  bladder	  cancer	  is	  indicative	  of	  muscle	  invasive	  disease.	  HIF-­‐2α	  is	  not	  present	  in	  normal	  bladder	  epithelial	  or	  superficial	  disease.	  HIF-­‐2α	  is	  much	  more	  prevalent	  in	  the	  muscle	  invasive	  compartment	  of	  the	  tumor	  than	  in	  the	  superficial	  compartment.	  This	  suggests	  that	  HIF-­‐2α	  may	  be	  involved	  in	  the	  invasion	  of	  bladder	  cancer.	  	  42	  	  	  Moreover,	  studies	  indicate	  HIF-­‐1α	  is	  expressed	  in	  some	  bladder	  tumors	  adjacent	  to	  patent	  vasculature—an	  area	  where	  oxygen	  levels	  should	  be	  normal.	  34	  	  We	  have	  shown	  HIF-­‐1α	  and	  HIF-­‐2α	  are	  present	  in	  invasive	  bladder	  cancer	  cells	  grown	  under	  normoxic	  conditions	  (personal	  communication:	  K	  Foreman,	  PhD).	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BLADDER	  CANCER	  Bladder	  cancer	  is	  a	  carcinoma	  of	  the	  epithelial	  lining	  of	  the	  bladder.	  	  There	  is	  no	  known	  genetic	  abnormality	  associated	  with	  bladder	  cancer,	  but	  the	  best-­‐known	  risk	  factor	  is	  cigarette	  smoking.	  43	  	  Bladder	  cancer	  is	  the	  fourth	  most	  common	  cancer	  in	  men	  and	  seventh	  most	  common	  in	  women	  in	  the	  United	  States.	  The	  American	  Cancer	  Society	  estimates	  that	  there	  will	  be	  74,000	  new	  cases	  diagnosed	  and	  16,000	  deaths	  due	  to	  bladder	  cancer	  in	  2015.	  	  44	  	  This	  is	  a	  disease	  primarily	  of	  the	  elderly,	  as	  the	  median	  age	  at	  diagnosis	  is	  65-­‐70	  years.	  	  43	  	  	  The	  tumor	  can	  be	  categorized	  into	  one	  of	  four	  stages:	  0-­‐IV.	  Stage	  0	  signifies	  a	  carcinoma	  in	  situ	  (CIS)	  or	  a	  papillary	  tumor	  that	  is	  growing	  in	  towards	  the	  hollow	  of	  the	  bladder,	  and	  has	  not	  infiltrated	  the	  connective	  tissue	  layer	  that	  surrounds	  the	  epithelial.	  Stage	  I	  signifies	  a	  tumor	  that	  has	  reached	  the	  connective	  tissue,	  but	  has	  not	  infiltrated	  the	  muscle	  of	  the	  bladder,	  nor	  has	  it	  spread	  beyond	  the	  bladder.	  Stage	  II	  signifies	  a	  tumor	  that	  has	  infiltrated,	  but	  has	  not	  passed	  all	  the	  way	  through	  the	  muscle	  layer	  of	  the	  bladder.	  Stage	  III	  signifies	  a	  tumor	  that	  has	  passed	  all	  the	  way	  through	  the	  muscle	  and	  into	  the	  fatty	  outermost	  layer	  of	  the	  bladder.	  A	  cancer	  at	  this	  stage	  may	  have	  infiltrated	  the	  vagina,	  prostate,	  or	  uterus,	  but	  has	  not	  reached	  the	  abdominal	  nor	  pelvic	  wall.	  Stage	  IV	  indicates	  a	  tumor	  that	  has	  broken	  through	  the	  bladder	  wall	  to	  the	  abdominal	  or	  pelvic	  wall,	  and	  may	  or	  may	  not	  have	  spread	  to	  lymph	  nodes	  or	  distant	  sites	  in	  the	  body.	  	  43	  	  Treatment	  strategies	  and	  outlook	  vary	  based	  on	  stage.	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Any	  tumor	  that	  has	  not	  invaded	  the	  muscle	  is	  categorized	  as	  non-­‐invasive,	  whereas	  a	  tumor	  that	  has	  infiltrated	  the	  muscle	  layer	  of	  the	  bladder	  is	  defined	  as	  muscle-­‐invasive.	  Once	  the	  disease	  has	  infiltrated	  the	  muscle,	  the	  survival	  outlook	  is	  significantly	  diminished.	  The	  likelihood	  that	  a	  patient	  will	  live	  at	  least	  5	  years	  after	  diagnosis	  is	  defined	  as	  a	  5-­‐year	  survival	  rate.	  Based	  on	  information	  between	  1988-­‐2001,	  the	  5-­‐year	  survival	  rate	  for	  an	  individual	  diagnosed	  with	  non-­‐muscle	  invasive	  disease	  is	  88%.	  This	  number	  drops	  to	  63%	  when	  the	  tumor	  has	  invaded	  the	  muscle,	  and	  to	  only	  15%	  when	  the	  tumor	  has	  reached	  the	  abdominal	  or	  pelvic	  wall	  (stage	  4,	  or	  advanced	  disease).	  	  44	  	  A	  contributing	  factor	  to	  the	  poor	  outlook	  is	  that	  50%	  of	  patients	  with	  muscle	  invasive	  bladder	  cancer	  develop	  metastatic	  disease	  within	  3	  years.	  45	  	  The	  current	  standard	  of	  care	  for	  muscle	  invasive	  bladder	  cancer	  may	  begin	  with	  neoadjuvent	  platinum	  based	  chemotherapy	  regimen	  of	  methotrexate,	  vinblastine,	  doxorubicin,	  and	  cisplatin	  (MVAC)	  or	  cisplatin	  plus	  gemcitabine	  in	  patients	  that	  are	  fit.	  	  46-­‐48	  	  This	  is	  followed	  with	  a	  radical	  cystectomy	  (removal	  of	  the	  bladder)	  accompanied	  with	  a	  hysterectomy	  in	  women	  and	  removal	  of	  the	  prostate	  in	  men.	  In	  less	  than	  5%	  of	  cases,	  a	  partial	  cystectomy	  may	  be	  performed	  instead.	  Adjuvant	  treatment	  of	  platinum	  based	  chemotherapy	  regimen,	  may	  be	  administered	  in	  hopes	  of	  preventing	  disease	  recurrence.	  Patients	  at	  risk	  for	  recurrence	  may	  also	  be	  considered	  for	  radiation	  therapy.	  	  Metastatic	  disease	  is	  responsible	  for	  approximately	  12,500	  deaths	  per	  year	  in	  the	  US,	  and	  remains	  an	  incurable	  disease.	  	  49	  	  In	  metastatic	  disease,	  cancer	  cells	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accumulate	  in	  pelvic	  lymph	  nodes,	  and	  then	  travel	  to	  distant	  parts	  of	  the	  body	  via	  the	  lymph	  vessels.	  Bladder	  cancer	  primarily	  metastasizes	  to	  the	  lung	  and	  bone,	  as	  well	  as	  liver	  and	  brain.	  Prognosis	  of	  advanced	  disease	  is	  poor,	  with	  median	  survival	  of	  only	  12	  months.	  	  50	  	  	  To	  treat	  advanced	  disease,	  a	  chemotherapy	  regimen	  of	  cisplatin	  plus	  gemcitabine	  is	  used	  in	  patients	  that	  are	  fit.	  This	  treatment	  increases	  survival	  to	  12.5-­‐14.3	  months.	  	  50,51	  	  Cisplatin	  is	  a	  platinum-­‐containing	  agent	  that	  works	  to	  crosslink	  DNA,	  resulting	  in	  programmed	  cell	  death.	  	  52	  	  Cisplatin	  is	  neurotoxic,	  nephrotoxic,	  and	  ototoxic.	  Its	  neurotoxicity	  and	  nephrotoxicity	  are	  dose-­‐limiting	  side	  effects.	  Many	  patients	  have	  concomitant	  kidney	  disease	  and	  are	  unable	  to	  tolerate	  even	  low	  doses	  of	  cisplatin.	  	  53	  	  Cisplatin’s	  toxicity	  is	  thought	  to	  be	  attributed	  to	  the	  accumulation	  of	  reactive	  oxygen	  species,	  as	  well	  as	  protein	  dysregulation	  within	  various	  cellular	  compartments.	  	  54	  	  Due	  to	  other	  co-­‐morbidities,	  such	  as	  poor	  renal	  function,	  lung	  or	  liver	  disease,	  half	  of	  patients	  with	  advanced	  disease	  are	  unfit	  for	  cisplatin	  therapy.	  In	  some	  of	  these	  patients,	  carboplatin	  is	  substituted	  for	  cisplatin,	  as	  it	  is	  less	  toxic.	  Carboplatin	  works	  in	  a	  similar	  manner	  to	  cisplatin,	  but	  has	  dose-­‐limiting	  toxicities	  of	  it	  own,	  such	  as	  meylosuppression,	  primarily	  thrombocytopenia.	  	  55	  	  More	  importantly,	  carboplatin	  is	  known	  to	  be	  inferior	  in	  the	  treatment	  of	  metastatic	  disease.	  	  55-­‐60	  	  Gemcitabine	  is	  common	  to	  both	  therapies,	  and	  is	  a	  nucleoside	  analog	  that	  arrests	  tumor	  growth	  by	  inducing	  apoptosis.	  	  61	  	  Gemcitabine	  acts	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synergistically	  in	  combination	  with	  both	  carboplatin	  and	  cisplatin	  in	  the	  treatment	  of	  bladder	  cancer.	  	  55,62,63	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EMETINE	  Emetine	  is	  a	  natural	  alkaloid	  of	  the	  root	  of	  ipecac,	  or	  ipecacuanha,	  a	  plant	  indigenous	  to	  Brazil	  (Figure	  5).	  Emetine’s	  initial	  use	  dates	  back	  as	  early	  as	  the	  17th	  century,	  and	  it	  continued	  to	  be	  used	  as	  an	  emetic	  and	  in	  the	  treatment	  of	  dysentery,	  caused	  by	  Entamoeba	  histolytica	  infection,	  until	  recent	  years	  	  64,65	  	  Emetine	  was	  available	  through	  the	  CDC	  for	  dysentery	  treatment	  until	  10-­‐15	  years	  ago	  when	  better	  alternatives	  became	  available.	  66	  	  Emetine	  has	  been	  available	  over	  the	  counter	  as	  syrup	  of	  ipecac	  but	  was	  removed	  from	  the	  market	  a	  few	  years	  ago,	  when	  it	  was	  no	  longer	  recommended	  to	  induce	  vomiting	  in	  children	  who	  had	  swallowed	  toxic	  chemicals,	  and	  it	  was	  being	  abused	  by	  anorexia	  and	  bulimia	  patients.	  67	  	  
	  
	  
Figure	  5:	  Structure	  of	  Emetine	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Emetine	  as	  an	  Anti-­Cancer	  Therapeutic	  The	  first	  use	  of	  emetine	  as	  an	  anticancer	  agent	  in	  1918	  is	  thanks	  to	  the	  belief	  held	  by	  Lewisohn	  that	  cancer	  was	  of	  parasitic	  origin.	  68	  	  Upon	  the	  potent	  anti-­‐parasitic	  effects	  observed	  of	  emetine,	  Lewisohn	  began	  the	  first	  study	  of	  emetine	  as	  an	  anticancer	  agent	  on	  human	  tumors.	  Apparent	  tumor	  regression	  was	  observed,	  but	  the	  studies	  were	  not	  pursued.	  68	  	  Van	  Hoosen	  also	  observed	  tumor	  regression	  with	  single	  agent	  emetine	  treatment	  and	  published	  her	  findings	  in	  1919.	  69	  	  	  In	  the	  late	  1960’s	  investigators	  began	  to	  study	  emetine	  as	  an	  anti-­‐tumor	  agent	  in	  more	  organized,	  clinical	  trials,	  and	  reported	  mixed	  results	  in	  a	  variety	  of	  malignancies.	  70-­‐72	  	  An	  initial	  study	  done	  by	  Abd-­‐Rabbo	  in	  the	  treatment	  of	  malignancy	  with	  emetine	  was	  in	  a	  patient	  that	  presented	  with	  a	  parasitic	  infestation.	  Due	  to	  the	  patient’s	  symptoms	  attributed	  to	  chronic	  myeloid	  leukemia,	  the	  investigator	  felt	  the	  patient	  unfit	  for	  the	  current	  therapy	  and	  chose	  to	  substitute	  emetine	  as	  treatment	  for	  parasitic	  infestation.	  To	  his	  surprise,	  the	  treatment	  of	  1	  mg/kg/day	  dehydroemetine	  (synthetically	  derived	  emetine)	  alone	  brought	  about	  a	  robust	  hemopoietic	  remission,	  similar	  to	  that	  seen	  upon	  chemotherapy.	  	  73	  	  To	  date,	  there	  have	  been	  two	  studies	  examining	  emetine’s	  anti-­‐neoplastic	  effect	  on	  bladder	  cancer.	  After	  his	  initial	  study	  in	  leukemia,	  Abd-­‐Rabbo	  conducted	  subsequent	  studies	  in	  the	  treatment	  of	  a	  variety	  of	  malignancies	  with	  dehydroemetine	  as	  a	  single-­‐agent	  therapy.	  Carcinoma	  of	  the	  bladder	  was	  one	  of	  several	  solid	  malignancies	  in	  his	  study.	  Nine	  cases	  of	  bladder	  cancer	  were	  treated	  with	  50	  mg/day	  of	  dehydroemetine	  (DHE)	  orally	  for	  21	  to	  30	  days.	  74	  	  The	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investigator	  notes	  the	  drug	  was	  surprisingly	  effective	  in	  the	  treatment	  of	  bladder	  carcinoma.	  The	  patients	  reported	  early	  improvement	  in	  symptoms	  of	  dysuria,	  hematuria,	  and	  incontinence,	  and	  a	  decrease	  in	  the	  size	  of	  tumor.	  74	  	  Two	  of	  the	  9	  patients	  were	  reported	  living	  after	  2	  years,	  the	  other	  7	  did	  not	  present	  for	  follow-­‐up.	  	  
74	  	  This	  same	  study	  reported	  mixed	  results	  in	  the	  treatment	  of	  other	  malignancies.	  74	  	  A	  few	  years	  later,	  in	  1971,	  a	  phase	  I	  clinical	  trial	  of	  emetine	  as	  a	  single	  agent	  in	  the	  treatment	  of	  a	  variety	  of	  malignant	  tumors	  was	  conducted	  by	  Panettiere	  and	  Coltman.	  The	  study	  included	  one	  patient	  with	  bladder	  cancer,	  who	  demonstrated	  stabilization	  of	  the	  disease	  upon	  17.4	  mg/kg	  emetine.	  The	  investigators	  concluded	  that	  a	  minimum	  of	  15	  mg/kg	  emetine	  as	  a	  single-­‐agent	  to	  be	  a	  reasonable	  treatment	  of	  various	  solid	  tumors.	  	  72	  	  	  Clinical	  studies	  with	  emetine	  were	  not	  pursued	  due	  to	  its	  marginal	  efficacy	  combined	  with	  severe	  side	  effects.	  Cardiotoxicity	  and	  muscle	  weakness	  caused	  the	  withdrawal	  of	  most	  patients	  enrolled	  in	  clinical	  studies	  examining	  the	  effectiveness	  of	  emetine	  as	  a	  single-­‐agent	  therapy.	  These	  patients	  received	  substantial	  doses	  of	  emetine,	  up	  to	  50	  mg/kg/day	  for	  30	  days.	  	  72,74	  	  Investigators	  suggest	  that	  lower	  doses	  are	  unlikely	  to	  have	  such	  severe	  side	  effects.	  72	  	  	  Minimal	  work	  has	  been	  done	  with	  emetine	  as	  part	  of	  a	  combination	  therapy.	  An	  investigation	  done	  by	  B.W.	  Street	  at	  Farnborough	  Hospital	  demonstrated	  a	  definite	  response	  in	  6	  distinct	  cases	  of	  lung	  carcinoma	  with	  combined	  therapy	  of	  emetine	  and	  cyclophosphamide.	  Street	  noted	  no	  toxic	  side	  effects	  from	  1.5	  mg/kg	  weekly	  IV	  emetine	  treatment,	  suggesting	  EKG	  monitoring	  as	  the	  only	  precaution	  in	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this	  treatment.	  	  75	  	  However,	  further	  clinical	  work	  with	  emetine	  either	  as	  a	  single-­‐agent	  or	  as	  part	  of	  a	  combination	  therapy	  has	  not	  been	  conducted.	  More	  recently,	  Larsson	  examined	  emetine	  in	  combination	  with	  doxorubicin,	  etoposide,	  oxaliplatin,	  and	  docetaxel	  in	  neuroendocrine	  cell	  lines	  (atypical	  and	  typical	  bronchial	  carcinoid	  and	  pancreatic	  carcinoid).	  	  76	  	  His	  studies	  demonstrated	  a	  synergistic	  response	  in	  all	  three	  cell	  lines	  with	  emetine	  plus	  etoposide,	  oxaliplatin,	  and	  docetaxel,	  and	  an	  additive	  response	  of	  emetine	  plus	  doxorubicin.	  Concentrations	  of	  emetine	  in	  these	  studies	  ranged	  from	  0.0062-­‐1.6µM.	  76	  	  His	  primary	  studies	  of	  synergism	  in	  cell	  culture	  suggest	  that	  combination	  therapy	  with	  emetine	  may	  be	  a	  reasonable	  candidate	  for	  clinical	  studies	  in	  patients	  with	  these,	  and	  possibly	  other,	  malignancies.	  	  76	  	  Emetine	  has	  also	  been	  shown	  to	  be	  anti-­‐proliferative	  in	  combination	  with	  cisplatin	  in	  leukemia.	  	  77	  	  Studies	  in	  leukemia	  cells	  demonstrate	  that	  the	  combined	  treatment	  of	  emetine	  plus	  cisplatin	  has	  an	  additive	  effect	  and	  increases	  cisplatin-­‐induced	  apoptosis.	  	  77	  	  The	  addition	  of	  emetine	  to	  many	  chemotherapy	  drugs	  has	  been	  demonstrated	  to	  be	  additive	  or	  synergistic	  in	  a	  number	  of	  malignant	  cell	  types,	  suggesting	  that	  its	  inclusion	  in	  a	  therapy	  regimen	  may	  be	  beneficial.	  	  A	  recent	  study	  by	  our	  group	  reported	  emetine	  to	  act	  synergistically	  with	  cisplatin	  in	  the	  treatment	  of	  bladder	  cancer	  cells,	  but	  not	  in	  normal	  bladder	  epithelial.	  	  78	  	  The	  same	  study	  found	  that	  the	  combined	  treatment	  caused	  cells	  to	  undergo	  growth	  arrest,	  rather	  than	  die	  via	  apoptosis.	  	  78	  	  However,	  the	  addition	  of	  emetine	  to	  the	  full	  standard	  of	  care	  chemotherapeutic	  regimen	  for	  bladder	  cancer	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has	  yet	  to	  be	  examined.	  The	  anti-­‐proliferative	  effects	  of	  emetine	  alone	  and	  in	  combination	  against	  carcinomas,	  specifically	  of	  the	  bladder,	  suggest	  the	  need	  for	  further	  research.	  	  
19	  
	  
Mechanism	  of	  Action	  Emetine’s	  primary	  mechanism	  of	  action	  is	  by	  inhibiting	  protein	  synthesis	  in	  mammalian	  and	  other	  cells.	  Grollman	  has	  extensively	  studied	  emetine’s	  activity	  in	  HeLa	  cells.	  His	  studies	  demonstrate	  the	  rapid	  inhibition	  of	  protein	  biosynthesis	  at	  the	  micromolar	  level,	  with	  50%	  inhibition	  at	  0.04	  µM	  and	  99%	  inhibition	  at	  1	  µM.	  	  64	   He	  observed	  a	  corresponding	  effect	  on	  DNA	  synthesis,	  but	  inhibition	  was	  never	  complete,	  as	  it	  was	  with	  protein	  synthesis.	  He	  also	  observed	  a	  slight	  decrease	  in	  RNA	  synthesis.	  	  79,80	   Studies	  on	  emetine’s	  effect	  on	  protein,	  DNA,	  and	  RNA	  synthesis	  have	  been	  conducted	  in	  other	  cell	  types	  and	  species.	  Emetine’s	  effect	  on	  protein	  synthesis	  is	  consistent,	  but	  its	  inhibition	  on	  DNA	  and	  RNA	  synthesis	  is	  varied.	  Milimolar	  concentrations	  of	  emetine	  inhibit	  protein	  synthesis,	  but	  do	  not	  affect	  DNA	  synthesis	  in	  Tetrahymena	  pyriformis.	  	  81	  	  Additionally,	  when	  rats	  were	  injected	  with	  a	  sub	  lethal	  dose	  of	  emetine,	  their	  liver	  and	  kidney	  protein	  concentrations	  were	  reduced,	  but	  RNA	  levels	  were	  unaffected.	  	  82	  	  At	  10	  mM,	  emetine	  inhibits	  protein	  synthesis	  by	  75%	  in	  gametophytes	  of	  Anemia	  Phylitidis,	  a	  higher	  plant.	  At	  a	  ten-­‐fold	  higher	  concentration,	  emetine	  inhibits	  protein	  synthesis	  by	  approximately	  95%	  in	  rabbit	  reticulocytes	  and	  the	  yeast	  S.	  cerevisiae.	  Although	  emetine	  consistently	  inhibits	  protein	  synthesis	  in	  protozoa,	  plants,	  yeast,	  and	  mammalian	  cells	  and	  tissues,	  it	  is	  shown	  to	  be	  ineffective	  as	  a	  protein	  synthesis	  inhibitor	  in	  E.	  coli	  and	  other	  prokaryotes.	  	  80	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Treatment	  of	  HeLa	  cells	  with	  1	  mM	  emetine	  causes	  a	  decrease	  in	  the	  number	  of	  free	  ribosomes,	  and	  an	  increase	  in	  the	  number	  of	  polyribosomes,	  as	  well	  as	  nascent	  peptide.	  	  79	  	  Emetine’s	  primary	  mechanism	  of	  action	  is	  by	  inhibiting	  protein	  biosynthesis.	  Emetine	  acts	  by	  interfering	  with	  the	  aminoacyl-­‐(t)RNA	  transfer	  reaction,	  	  and	  is	  specific	  to	  this	  step	  in	  protein	  biosynthesis.	  	  80	  	  By	  preventing	  the	  transfer	  of	  amino	  acids	  on	  the	  polyribosome,	  emetine	  causes	  the	  nascent	  polypeptide	  to	  remain	  attached	  to	  the	  ribosome.	  	  80	  	  Additional	  studies	  done	  by	  Grollman	  suggest	  that	  emetine	  does	  not	  bind	  to	  the	  ribosome,	  either	  single	  or	  poly,	  but	  likely	  interferes	  with	  the	  enzymatic	  formation	  of	  the	  peptide	  bond	  between	  amino	  acids	  while	  docked	  in	  the	  ribosome.	  	  79,80	  	  However,	  a	  study	  done	  by	  Jimenez	  et	  al.	  suggests	  that	  emetine	  binds	  directly	  with	  the	  40S	  subunit	  of	  the	  ribosome	  to	  interfere	  with	  the	  animoacyl-­‐tRNA	  transfer	  reaction.	  	  83	  	  Although	  these	  two	  studies	  disagree	  about	  emetine’s	  exact	  site	  of	  action,	  they	  confirm	  that	  its	  mode	  of	  action	  is	  by	  preventing	  movement	  of	  the	  mRNA	  along	  the	  ribosome.	  	  83	  	  Emetine’s	  effect	  on	  protein	  synthesis	  is	  confined	  to	  the	  cytoplasm,	  as	  concentrations	  that	  completely	  block	  cytoplasmic	  protein	  synthesis	  do	  not	  affect	  mitochondrial	  protein	  synthesis.	  	  84	  	  The	  effects	  of	  emetine	  on	  macromolecule	  synthesis	  are	  structurally	  specific.	  Emetine’s	  isomers,	  isoemetine,	  and	  O-­‐methylpsychotrine,	  show	  less	  than	  1%	  of	  the	  activity	  of	  emetine.	  The	  therapeutic	  and	  toxic	  effects	  of	  emetine	  may	  likely	  be	  accounted	  for	  by	  the	  metabolic	  disturbance	  caused	  by	  protein	  biosynthesis	  inhibition.	  	  64	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Emetine	  and	  HIF	  
	   Emetine	  has	  been	  shown	  to	  rapidly	  and	  preferentially	  downregulate	  HIF-­‐2α	  protein,	  but	  not	  mRNA,	  in	  a	  concentration	  dependent	  manner	  in	  clear	  cell	  renal	  carcinoma	  (CCRCC)	  cell	  lines	  at	  concentrations	  as	  low	  as	  50	  nM.	  13	  	  In	  these	  cells,	  HIF-­‐2α	  protein	  appears	  to	  be	  degraded	  in	  the	  proteasome	  in	  response	  to	  emetine	  treatment.	  13	  	  Moreover,	  1	  µM	  emetine	  was	  shown	  to	  reduce	  the	  level	  of	  secreted	  VEGF	  and	  TGF-­‐α	  (HIF-­‐2α	  transcription	  products)	  by	  75%.	  	  13	  	  This	  suggests	  that	  emetine’s	  downregulation	  of	  HIF-­‐2α	  has	  a	  functional	  effect	  on	  the	  cell.	  	  Emetine	  has	  also	  been	  found	  to	  downregulate	  levels	  of	  nuclear	  HIF-­‐1α	  but	  not	  HIF-­‐β	  in	  a	  human	  breast	  cancer	  cell	  line	  at	  concentrations	  as	  low	  as	  0.11	  µM.	  Additionally,	  0.3	  µM	  emetine	  treatment	  decreased	  the	  level	  of	  VEGF	  secreted	  by	  these	  cells	  by	  50%,	  again	  suggesting	  emetine	  may	  affect	  the	  function	  of	  the	  cell	  by	  downregulating	  HIF-­‐regulated	  genes.	  	  85	  	  Emetine’s	  effect	  on	  HIF	  proteins	  in	  other	  cancers	  has	  not	  yet	  been	  examined.	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OBJECTIVES	  AND	  HYPOTHESIS	  The	  goal	  of	  this	  project	  is	  to	  test	  emetine’s	  efficacy	  as	  an	  anticancer	  therapeutic	  in	  combination	  with	  standard	  of	  care	  chemotherapeutic	  regimens	  in	  bladder	  cancer,	  and	  work	  to	  define	  the	  mechanism	  behind	  its	  action.	  We	  proposed	  the	  following	  hypothesis	  for	  this	  project.	  	  Emetine,	  combined	  with	  standard	  of	  care	  chemotherapeutic	  regimens,	  may	  benefit	  bladder	  cancer	  patients	  by	  acting	  to	  enhance	  growth	  arrest	  and/or	  killing	  of	  bladder	  cancer	  cells.	  	  Emetine	  may	  act,	  at	  least	  in	  part,	  by	  altering	  hypoxia	  signaling.	  	  SPECIFIC	  AIMS	  AIM	  1A:	  Determine	  if	  the	  addition	  of	  emetine	  to	  the	  standard	  of	  care	  chemotherapy	  regimen	  decreases	  proliferation	  in	  bladder	  cancer	  cells	  Previous	  work	  in	  the	  Foreman	  lab	  has	  demonstrated	  that	  the	  addition	  of	  emetine	  to	  cisplatin	  causes	  a	  synergistic	  decrease	  in	  proliferation	  of	  bladder	  cancer	  epithelial	  cells.	  78	  	  It	  is	  important,	  however,	  to	  examine	  the	  addition	  of	  emetine	  to	  the	  standard	  of	  care	  therapy	  of	  cisplatin	  plus	  gemcitabine	  and	  carboplatin	  plus	  gemcitabine	  as	  they	  are	  a	  better	  representation	  of	  what	  patients	  receive	  in	  the	  clinic.	  	  	  AIM	  1B:	  Examine	  what	  is	  causing	  the	  decrease	  in	  cell	  proliferation	  	   Using	  a	  variety	  techniques,	  we	  will	  work	  to	  elucidate	  the	  mechanism	  behind	  the	  decrease	  in	  cell	  proliferation	  observed	  upon	  the	  addition	  of	  emetine	  to	  both	  cisplatin-­‐gemcitabine	  and	  carboplatin-­‐gemcitabine	  standard	  of	  care.	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CHAPTER	  2	  	  
MATERIALS	  AND	  METHODS	  
Cell	  Culture	  UMUC3	  and	  HT1376	  muscle	  invasive	  bladder	  cancer	  cell	  lines	  were	  cultured	  under	  standard	  conditions	  in	  Dulbecco’s	  modified	  Eagle’s	  media	  containing	  10%	  fetal	  bovine	  serum	  (FBS),	  2	  mmol/L	  L-­‐glutamine,	  100	  U/ml	  penicillin,	  and	  100μg/ml	  streptomycin.	  The	  T24	  muscle	  invasive	  cell	  line	  was	  cultured	  under	  standard	  conditions	  in	  McCoys	  media	  containing	  10%	  FBS,	  2	  mmol/L	  L-­‐glutamine,	  100	  U/ml	  penicillin,	  and	  100μg/ml	  streptomycin.	  Normal	  bladder	  epithelial	  cells	  (Cell-­‐N-­‐Tec)	  were	  cultured	  in	  standard	  conditions	  in	  CNT-­‐PR	  media	  as	  recommended	  by	  the	  manufacturer.	  The	  cultures	  were	  confirmed	  mycoplasma	  negative	  through	  periodic	  testing	  using	  MycoAlert	  Mycoplasma	  Detection	  Kit	  (Lonza).	  Cells	  were	  maintained	  at	  37oC	  in	  5%	  CO2	  and	  sub-­‐cultured	  when	  they	  reached	  80-­‐90%	  confluence	  (every	  2-­‐5	  days).	  
Pharmaceutical	  Reagents	  Drugs	  used	  in	  this	  project	  included	  emetine	  dihydrochloride	  hydrate	  (Sigma-­‐E237)	  suspended	  in	  sterile	  Milli-­‐Q	  water	  and	  stored	  at	  -­‐4oC,	  Cisplatin	  (Selleck	  Chemical-­‐	  S1166)	  suspended	  in	  sterile	  dimethyl	  sulfoxide	  (DMSO)	  and	  stored	  at	  -­‐80oC,	  Carboplatin	  (Selleck	  Chemical-­‐	  S1215)	  resuspended	  in	  sterile	  DMSO	  and	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stored	  at	  -­‐80oC,	  and	  Gemcitabine	  HCL	  (Selleck	  Chemical-­‐	  S1149)	  resuspended	  in	  sterile	  Milli-­‐Q	  water	  and	  stored	  at	  -­‐80oC.	  	  
Proliferation	  Assay	  	  Proliferation	  was	  assessed	  using	  a	  3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,	  5-­‐diphenyltetrazolium	  bromide	  (MTT)	  assay. Cells	  were	  plated	  at	  a	  density	  of	  2,500-­‐5,000	  cells/well	  in	  a	  96	  well	  plate.	  Cells	  were	  allowed	  to	  adhere	  overnight	  and	  were	  then	  treated	  with	  individual	  drugs,	  drug	  combinations,	  or	  left	  untreated	  as	  a	  control.	  Forty-­‐eight	  hours	  after	  treatment,	  MTT	  was	  added	  to	  each	  well.	  MTT	  (Sigma-­‐M2128)	  was	  resuspended	  at	  5	  mg/ml	  in	  PBS,	  filtered	  to	  remove	  particulates	  and	  added	  for	  a	  final	  concentration	  of	  0.5	  mg/ml.	  The	  solution	  was	  gently	  mixed,	  and	  the	  cells	  incubated	  at	  370C	  for	  2	  hours.	  The	  media	  was	  removed,	  cells	  lysed	  in	  100	  µL	  DMSO,	  and	  the	  absorbance	  read	  at	  560nm.	  Background	  absorbance	  at	  670nm,	  as	  well	  as	  the	  absorbance	  from	  wells	  containing	  no	  cells,	  was	  subtracted	  from	  these	  values.	  Proliferation	  was	  reported	  as	  a	  percentage	  of	  no	  drug	  (untreated)	  control	  samples.	  Each	  condition	  was	  performed	  in	  quadruplicate.	  The	  half	  maximal	  inhibitory	  concentration	  (IC50)	  was	  calculated	  using	  PRISM	  software.	  Drug	  synergy	  was	  assessed	  via	  the	  Chou-­‐Talalay	  Median	  Effects	  method	  with	  the	  combination	  index	  (CI)	  calculated	  via	  CalcuSyn	  software	  (Biosoft).	  86,87	  	  A	  CI	  value	  of	  0.2-­‐0.8	  indicates	  synergy,	  a	  CI	  value	  from	  0.9-­‐1.1	  indicates	  an	  additive	  effect	  and	  a	  CI	  value	  >1.1	  indicates	  an	  antagonistic	  response.	  	  86,87	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Trypan	  Blue	  Exclusion	  Normal	  bladder	  epithelial	  cells	  were	  plated	  at	  a	  density	  of	  3x104	  –	  8x104	  cells/well	  in	  a	  24-­‐well	  plate.	  Cells	  were	  treated	  with	  drug	  alone	  or	  in	  combination	  when	  cells	  were	  at	  least	  50%	  confluent	  (1-­‐3	  days	  after	  plating).	  	  Forty-­‐eight	  hours	  after	  treatment,	  cells	  were	  lifted	  with	  accutase	  (Cell-­‐N-­‐Tec)	  and	  resuspended	  in	  a	  1:1	  ratio	  of	  media:trypan	  blue.	  Cells	  were	  counted	  using	  a	  hemocytometer.	  Several	  of	  the	  higher	  concentrations	  inhibited	  proliferation	  to	  the	  extent	  that	  there	  were	  fewer	  than	  100	  cells	  recovered,	  limiting	  the	  total	  cell	  count	  for	  that	  condition.	  A	  minimum	  of	  150	  cells	  were	  counted	  per	  condition,	  whenever	  possible.	  	  
Nuclear	  Protein	  Extraction	  Cultured	  cells	  at	  80-­‐90%	  confluency	  were	  placed	  in	  an	  ice	  bath	  and	  rinsed	  with	  cold	  PBS.	  Cells	  were	  scraped	  into	  1	  mL	  cold	  PBS	  and	  transferred	  to	  a	  microfuge	  tube.	  The	  cells	  were	  pelleted	  with	  a	  low	  speed	  centrifugation	  at	  4oC.	  The	  pellets	  were	  weighed,	  and	  5	  µL/mg	  KCl	  buffer	  (10	  mM	  Hepes-­‐	  pH	  7.9,	  10	  mM	  KCl,	  1	  mM	  EDTA,	  1	  mM	  EGTA)	  with	  HALT	  protease	  and	  phosphatase	  inhibitors	  was	  added	  to	  dissociate	  and	  swell	  cells.	  Samples	  were	  incubated	  on	  ice	  for	  10	  minutes.	  10%	  NP-­‐40	  solution	  was	  added	  at	  a	  volume	  of	  approximately	  1/18	  of	  the	  KCL	  buffer,	  the	  cells	  vortexed,	  and	  then	  incubated	  on	  ice	  for	  1	  minute	  to	  lyse	  cells.	  Samples	  were	  centrifuged	  on	  top	  speed	  for	  30	  seconds	  to	  pellet	  nuclei.	  NaCl	  buffer	  (20	  mM	  Hepes,	  0.4	  M	  NaCl,	  1	  mM	  EDTA,	  1	  mM	  EGTA)	  at	  approximately	  1/8	  the	  volume	  of	  the	  first	  salt	  buffer	  was	  added	  to	  nuclear	  pellet.	  Samples	  placed	  in	  shaker	  at	  1450	  rpm	  at	  4oC	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for	  40	  minutes.	  Samples	  were	  centrifuged	  at	  top	  speed	  for	  10	  minutes	  to	  pellet	  debris.	  Nuclear	  extracts	  were	  stored	  at	  -­‐80oC	  in	  20-­‐30	  µL	  aliquots.	  	  	  
Whole	  Cell	  Protein	  Extraction	  Cultured	  cells	  at	  80-­‐90%	  confluency	  were	  placed	  in	  an	  ice	  bath	  and	  rinsed	  with	  cold	  PBS.	  Cells	  were	  scraped	  into	  1	  mL	  cold	  PBS	  and	  transferred	  to	  a	  microfuge	  tube.	  Plates	  were	  rinsed	  with	  cold	  PBS	  to	  collect	  any	  remaining	  cells,	  which	  was	  added	  to	  the	  microfuge	  tubes.	  Samples	  were	  centrifuged	  at	  low	  speed	  for	  5	  minutes,	  and	  supernatant	  removed.	  	  100	  µL	  of	  ice	  cold	  RIPA	  buffer	  (PBS	  with	  1%	  NP-­‐40	  and	  0.1%	  SDS)	  with	  5	  mg	  sodium	  deoxycholate	  per	  mL	  RIPA	  plus	  HALT	  protease	  and	  phosphatase	  inhibitors	  was	  added	  to	  pellet.	  Sample	  was	  sonicated	  on	  ~10%	  duty	  cycle	  and	  output	  of	  3.5	  for	  4-­‐5	  pulses	  and	  repeated.	  Samples	  were	  shaken	  at	  1450	  rpm	  at	  4oC	  for	  1	  hour,	  and	  centrifuged	  for	  20	  minutes	  at	  top	  speed	  at	  4oC.	  Supernatant	  was	  frozen	  at	  -­‐80oC	  in	  20-­‐40	  µL	  aliquots.	  	  
Immunoblotting	  Protein	  concentration	  of	  nuclear	  or	  whole	  cell	  extracts	  was	  determined	  using	  Pierce	  micro	  plate	  BCA-­‐Protein	  Assay	  Kit	  according	  to	  manufacturer’s	  instructions.	  50-­‐100	  µg	  protein	  samples	  were	  added	  to	  an	  appropriate	  amount	  of	  SDS-­‐PAGE	  loading	  buffer	  containing	  beta-­‐mercaptoethanol	  and	  heat	  denatured	  for	  10	  minutes	  prior	  to	  loading	  onto	  an	  SDS-­‐PAGE	  denaturing	  gel.	  Samples	  were	  run	  at	  100	  volts	  then	  transferred	  to	  Immobilon	  PVDF	  membrane.	  Even	  protein	  loading	  was	  verified	  by	  Ponceau	  red	  stain	  of	  membrane	  after	  transfer.	  Primary	  antibodies	  used	  included	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HIF-­‐1α	  (1:500,	  BD	  Bioscience-­‐610959),	  HIF-­‐2α	  (1	  µg/ml,	  R&D	  Systems-­‐AF2886),	  HIF-­‐β/ARNT	  (1:1000,	  Cell	  Signaling-­‐D28F3),	  Lamin	  A/C	  (1:1000,	  Cell	  Signaling-­‐2032S).	  Primary	  antibodies	  were	  detected	  using	  species-­‐specific,	  horseradish	  peroxidase	  labeled	  secondary	  antibodies	  (1:1000,	  BD	  Bioscience).	  Membranes	  were	  imaged	  using	  SuperSignal	  West	  Pico	  Chemiluminescent	  Substrate	  (Thermo	  Scientific-­‐34078)	  on	  a	  Fujifilm	  imager.	  	  
Detection	  of	  Autophagy:	  monodansylcadaverine	  staining	  of	  autophagosomes	  	  Cells	  were	  plated	  on	  sterile	  cover	  slips	  at	  a	  density	  of	  1.1	  x105	  cells	  per	  well	  of	  a	  6-­‐well	  plate.	  Cells	  were	  allowed	  to	  adhere	  to	  the	  cover	  slips	  overnight,	  then	  treated	  with	  single-­‐agent	  or	  combination	  of	  emetine,	  cisplatin,	  and/or	  gemcitabine.	  Forty-­‐eight	  hours	  after	  drug	  treatment,	  50	  µM	  monodansylcadaverine	  (MDC,	  resuspended	  in	  sterile	  DMSO)	  (Sigma-­‐D4008)	  was	  added	  and	  cells	  incubated	  at	  37oC	  for	  one	  hour.	  Cells	  were	  washed	  3X	  with	  1%	  FA	  (Difco)	  buffer	  and	  mounted	  on	  slides	  using	  Vectasheild	  mounting	  medium	  (Vector	  Laboratories)	  and	  immediately	  imaged	  with	  a	  fluorescent	  microscope	  under	  excitation	  wavelength	  of	  335nm.	  Ten	  random	  high	  powered	  images	  were	  captured	  per	  slide	  using	  Olympus	  cellSens	  Dimensions	  1.6	  software.	  MDC	  is	  an	  auto	  fluorescent	  compound	  that	  accumulates	  in	  autophagosomes	  that	  accrue	  during	  autophagy.	  88	  	  To	  quantitate	  the	  percentage	  of	  autophagy	  positive	  cells,	  ImageJ	  software	  was	  used.	  The	  cell	  counter	  add-­‐in	  was	  utilized	  to	  determine	  the	  total	  number	  of	  cells	  in	  each	  image	  and	  then	  fluorescent	  cells	  above	  a	  pre-­‐set	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threshold	  were	  highlighted	  and	  counted	  as	  positive.	  The	  intensity	  threshold	  was	  set	  so	  that	  3%	  or	  less	  of	  untreated	  cells	  were	  positive.	  A	  minimum	  of	  500	  cells	  per	  condition	  were	  counted.	  	  
Immunoprecipitation	  Cultured	  cells	  at	  80-­‐90%	  confluency	  were	  rinsed	  twice	  in	  ice-­‐cold	  PBS.	  900	  
µL	  of	  1X	  Cell	  Lysis	  Buffer	  (Cell	  Signaling-­‐9803)	  containing	  1	  mM	  phenylmethylsulfonyl	  fluoride	  (PMSF)	  (Roche;	  diluted	  in	  DMSO)	  and	  HALT	  protease	  and	  phosphatase	  inhibitors	  was	  added	  drop	  wise	  to	  one	  T150	  plate,	  and	  incubated	  on	  ice	  for	  5	  minutes.	  Cells	  were	  scraped	  into	  a	  microfuge	  tube	  and	  flash	  frozen	  in	  ethanol	  and	  dry	  ice,	  or	  overnight	  at	  -­‐80oC.	  Lysates	  were	  thawed,	  and	  sonicated	  4-­‐5X	  on	  a	  duty	  cycle	  of	  ~10%	  and	  an	  output	  setting	  of	  4.	  Samples	  were	  spun	  at	  14,000	  x	  g	  to	  pellet	  cellular	  debris.	  The	  protein	  concentration	  was	  determined	  using	  Pierce	  micro	  plate	  BCA-­‐Protein	  Assay	  Kit	  according	  to	  manufacturer’s	  instructions.	  Samples	  were	  diluted	  with	  1X	  lysis	  buffer	  accordingly	  to	  equalize	  the	  protein	  concentration.	  Lysates	  were	  pre-­‐cleared	  by	  adding	  5	  µg	  of	  irrelevant	  antibody	  of	  appropriate	  species	  and	  isotype	  control	  to	  1	  mL	  of	  lysate,	  and	  rotated	  at	  4oC	  for	  60	  minutes	  [abcam-­‐ab18469	  (mouse	  IgG2b)	  &	  ab27472	  (rabbit	  IgG),	  and	  Santa	  Cruz	  Biotechnology-­‐	  sc2028(goat	  IgG)].	  75	  µL	  of	  Protein	  A/G	  PLUS-­‐Agarose	  beads	  (Santa	  Cruz	  Biotechnolgy-­‐sc2003)	  pre-­‐washed	  in	  1X	  lysis	  buffer	  plus	  HALT	  protease	  and	  phosphatase	  inhibitors	  were	  added	  to	  each	  tube	  and	  rotated	  at	  4oC	  for	  30-­‐60	  minutes.	  Beads	  were	  pelleted	  by	  centrifuge	  at	  low	  speed	  for	  2-­‐3	  minutes.	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Supernatant	  was	  removed	  and	  transferred	  to	  new,	  pre-­‐chilled	  microfuge	  tube.	  5	  µg	  of	  antibody,	  either	  HIF-­‐1α	  (Santa	  Cruz-­‐	  sc10790,	  or	  abcam-­‐	  ab1)	  or	  HIF-­‐2α	  (R&D	  Systems-­‐AF2886)	  was	  added	  to	  each	  tube	  and	  rotated	  overnight	  at	  4oC.	  50	  µL	  of	  conditioned	  beads	  were	  added	  and	  rotated	  at	  4oC	  for	  1-­‐2	  hours.	  Beads	  were	  pelleted	  at	  low	  speed	  for	  2-­‐3	  minutes	  at	  4oC,	  and	  washed	  in	  1X	  lysis	  buffer	  plus	  HALT	  protease	  and	  phosphatase	  inhibitors	  4	  times,	  and	  resuspended	  in	  30	  µL	  50µM	  Tris	  pH	  8.	  	  
Click-­iT	  Metabolic	  Labeling	  of	  Proteins	  	  Cells	  were	  incubated	  in	  DMEM	  containing	  2%FBS	  with	  or	  without	  100	  µM	  CoCl2	  for	  6	  hours.	  The	  media	  was	  replaced	  with	  methionine-­‐free	  media	  containing	  2%	  FBS,	  and	  increasing	  concentrations	  of	  emetine	  were	  added	  for	  1	  hour.	  Media	  was	  removed,	  and	  plates	  rinsed	  with	  warm	  PBS.	  AHA,	  or	  L-­‐azidohomoalaine	  (Invitrogen-­‐C10102),	  was	  added	  to	  media	  at	  a	  final	  concentration	  of	  50	  µM	  for	  three	  hours.	  For	  immunoprecipitation	  experiments,	  cells	  were	  lysed	  and	  either	  HIF-­‐1α or	  HIF-­‐2α	  total	  protein	  was	  immunoprecipitated	  as	  stated	  above.	  Newly	  synthesized	  proteins	  were	  selected	  using	  Click-­‐iT	  Protein	  Reaction	  Buffer	  Kit	  (Invitrogen-­‐C10276).	  50	  µL	  alkyne	  solution	  was	  added	  to	  beads,	  and	  vortexed	  for	  5	  seconds.	  5	  
µL	  of	  CuSO4	  solution	  was	  added	  to	  each	  tube.	  5	  µL	  of	  reconstituted	  component	  D	  was	  added	  and	  tube	  was	  vortexed	  for	  5	  seconds.	  Tubes	  were	  held	  on	  ice	  for	  at	  least	  2,	  but	  no	  more	  than	  3	  minutes.	  10	  µL	  of	  reaction	  buffer	  additive	  2	  was	  added	  to	  each	  tube,	  and	  vortexed	  for	  5	  seconds.	  Tubes	  were	  rotated	  at	  4oC	  for	  1	  hour.	  Beads	  were	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washed	  1X	  in	  TBS.	  Proteins	  were	  eluted	  by	  heating	  in	  40	  µL	  of	  2X	  Laemmli	  Sample	  Buffer	  (Bio	  Rad-­‐	  161-­‐0737EDU)	  plus	  beta-­‐mercaptoethanol	  for	  5	  minutes	  at	  95oC.	  Beads	  were	  precipitated	  by	  centrifuge	  at	  high	  speed	  for	  1	  minute.	  The	  entire	  supernatant	  was	  loaded	  onto	  8%	  SDS-­‐Page	  denaturing	  gel	  for	  western	  blot	  analysis.	  Primary	  antibodies	  used	  were	  HIF-­‐1α,	  or	  HIF-­‐2α.	  Streptavidin-­‐HRP	  (1:5,000-­‐1:7,000,	  Invitrogen-­‐43-­‐4323)	  was	  used	  to	  detect	  biotin.	  To	  evaluate	  total	  protein	  synthesis,	  proteins	  were	  precipitated	  following	  the	  click	  reaction,	  as	  stated	  above,	  by	  adding	  600	  µL	  methanol,	  150	  µL	  chloroform,	  and	  400µL	  of	  milli-­‐Q	  water	  to	  microfuge	  tubes	  immediately	  after	  the	  1	  hour	  rotation.	  Tubes	  were	  briefly	  vortexed,	  and	  centrifuged	  at	  high	  speed	  for	  5	  minutes.	  Upon	  removal	  of	  the	  upper	  aqueous	  phase,	  another	  450	  µL	  of	  methanol	  was	  added,	  samples	  were	  vortexed	  and	  centrifuged	  at	  high	  speed	  to	  pellet	  protein.	  Samples	  were	  washed	  once	  with	  methanol	  and	  allowed	  to	  air	  dry	  in	  microfuge	  tube	  covered	  with	  a	  Kim	  wipe	  15	  minutes	  to	  overnight.	  Protein	  was	  resuspended	  in	  1X	  loading	  buffer	  plus	  beta-­‐mercaptoethanol,	  vortexed	  for	  10	  minutes	  and	  boiled	  at	  70oC	  for	  10	  minutes.	  Samples	  were	  run	  on	  an	  8%	  SDS-­‐Page	  denaturing	  gel	  for	  western	  blot	  and	  Streptavidin-­‐HRP	  was	  used	  to	  detect	  biotin.	  	  
Propidium	  Iodide	  Staining	  Cells	  were	  plated	  at	  a	  density	  of	  5x105	  in	  p60	  dishes	  and	  allowed	  to	  adhere	  overnight.	  Cells	  were	  treated	  with	  drug	  alone	  or	  in	  combination,	  media	  removed,	  and	  cells	  were	  retreated	  where	  applicable.	  When	  treatment	  schedule	  was	  complete,	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media	  from	  plates	  were	  collected	  in	  a	  15	  ml	  conical	  tube.	  Attached	  cells	  were	  rinsed	  once	  with	  PBS,	  lifted	  with	  trypsin	  and	  added	  to	  tube.	  Cells	  were	  pelleted	  by	  low	  speed	  centrifugation	  at	  4oC.	  Supernatant	  was	  removed,	  and	  cells	  resuspended	  in	  FACS	  buffer	  (1%	  FA	  buffer,	  1%	  FBS,	  0.1%	  sodium	  azide).	  At	  least	  1x106	  cells	  were	  transferred	  to	  a	  FACS	  tube	  and	  washed	  1X	  with	  FACS	  buffer.	  Supernatant	  was	  decanted,	  and	  100	  µL	  cold	  FBS	  was	  added	  to	  each	  tube.	  600	  µL	  ice	  cold	  100%	  ethanol	  was	  added	  to	  each	  tube	  while	  gently	  vortexing.	  Cells	  were	  incubated	  on	  ice	  for	  30	  minutes.	  2	  mL	  of	  cold	  FACS	  buffer	  was	  added,	  and	  cells	  were	  pelleted	  by	  centrifuge	  at	  low	  speed	  at	  4oC.	  	  Liquid	  was	  decanted,	  and	  10	  µL	  of	  10	  µg/ml	  RNAse,	  DNAse	  Free	  (Thermo	  Scientific-­‐ENO531)	  was	  added	  to	  cells	  plus	  490	  µL	  PBS.	  Solution	  was	  mixed	  and	  incubated	  at	  37oC	  for	  15	  minutes.	  10	  µL	  of	  5	  mg/ml	  propidium	  iodide	  in	  PBS	  (Sigma	  P-­‐4170)	  plus	  490	  µL	  PBS	  was	  added	  to	  suspension.	  Samples	  were	  mixed	  gently	  and	  incubated	  for	  at	  least	  1	  hour	  at	  4oC	  before	  analysis.	  	  For	  cell	  cycle	  analysis	  via	  propidium	  iodide	  (PI)	  incorporation,	  samples	  were	  run	  on	  CantoII	  flow	  cytometer.	  Results	  were	  analyzed	  via	  FlowJo	  software.	  Gates	  were	  drawn	  manually	  for	  each	  experiment	  based	  on	  the	  untreated	  sample,	  and	  applied	  to	  the	  remaining	  samples	  for	  analysis.	  	  
Detection	  of	  Apoptosis:	  Annexin	  V/PI	  staining.	  	  Cells	  were	  plated	  at	  a	  density	  of	  5x105	  in	  p60	  dishes,	  and	  allowed	  to	  adhere	  overnight.	  Cells	  were	  treated	  with	  drug	  alone	  or	  in	  combination,	  media	  removed,	  and	  cells	  were	  retreated	  where	  applicable.	  When	  treatment	  schedule	  was	  complete,	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media	  from	  plates	  were	  collected	  in	  15	  ml	  conical	  tubes.	  Plates	  were	  rinsed	  with	  PBS,	  which	  was	  added	  to	  conical.	  Cells	  were	  trypsinized	  for	  5	  minutes	  and	  added	  to	  conical.	  Samples	  were	  centrifuged	  for	  5	  minutes	  at	  low	  speed	  at	  4oC.	  Cells	  were	  resuspended	  in	  5	  mL	  of	  cold	  PBS.	  The	  Beckman	  coulter	  Annexin	  V-­‐FITC	  kit	  (PN-­‐IM3546)	  was	  used	  to	  detect	  Annexin	  V	  positive	  cells	  following	  the	  manufacturer’s	  instructions.	  Briefly,	  1x105	  –	  3x105	  cells	  were	  transferred	  to	  a	  FACS	  tube	  on	  ice	  and	  resuspended	  in	  100	  µL	  cold	  1X	  binding	  buffer	  from	  Annexin	  V-­‐FITC	  kit.	  1	  µL	  Annexin	  V-­‐FITC	  was	  added	  followed	  by	  5	  µL	  of	  PI.	  Samples	  were	  incubated	  on	  ice	  for	  15	  minutes	  in	  the	  dark.	  400	  µL	  1X	  binding	  buffer	  was	  added	  and	  samples	  were	  analyzed	  on	  CantoII	  flow	  cytometer	  within	  30	  minutes.	  Data	  was	  analyzed	  using	  FlowJo	  software.	  Quadrants	  were	  drawn	  so	  that	  populations	  of	  cells	  were	  uninterrupted,	  and	  fit	  squarely	  into	  one	  quadrant.	  	  89	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CHAPTER	  3	  	  
RESULTS	  AIM	  IA:	  DETERMINE	  IF	  THE	  ADDITION	  OF	  EMETINE	  TO	  THE	  STANDARD-­‐OF-­‐CARE	  CHEMOTHERAPY	  REGIMEN	  DECREASES	  PROLIFERATION	  IN	  BLADDER	  CANCER	  CELLS	  To	  answer	  this	  question,	  we	  first	  determined	  the	  value	  of	  each	  drug	  that	  inhibited	  cell	  growth	  in	  vitro	  by	  50%,	  or	  the	  IC50	  value,	  via	  an	  MTT	  proliferation	  assay.	  We	  used	  these	  values	  as	  reference	  points	  on	  which	  to	  base	  drug	  concentrations	  used	  in	  all	  subsequent	  experiments,	  including	  synergy	  proliferation	  assays.	  With	  the	  aid	  of	  PRISM	  software,	  we	  determined	  the	  following	  IC50	  values	  for	  cisplatin,	  carboplatin,	  gemcitabine,	  and	  emetine:	  	  
Table	  1:	  Experimentally	  Determined	  IC50	  values.	  	   Cisplatin	   Carboplatin	   Gemcitabine	   Emetine	  UMUC3	   6.8	  µM	   73	  µM	   31	  nM	   30	  nM	  HT1376	   4.2	  µM	   38.9	  µM	   >1000	  µM	   24.6	  nM	  T24	   4.4	  µM	   69.2	  µM	   20	  nM	   66	  nM	  Normal	  Bladder	  Epithelial	   24.6	  µM	   281	  µM	   >100	  µM	   3.22	  µM	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The	  Addition	  of	  Emetine	  to	  Cisplatin-­Gemcitabine	  Standard	  of	  Care	  Results	  in	  
an	  Additive	  Decrease	  in	  Cell	  Proliferation	  	  Previous	  work	  in	  the	  Foreman	  lab	  has	  demonstrated	  that	  emetine	  acts	  synergistically	  with	  cisplatin	  to	  decrease	  cell	  proliferation	  in	  invasive	  bladder	  cancer	  cell	  lines.	  78	  	  Here,	  we	  examine	  the	  addition	  of	  emetine	  to	  cisplatin	  plus	  gemcitabine,	  or	  carboplatin	  plus	  gemcitabine,	  as	  it	  is	  a	  better	  representation	  of	  what	  patients	  receive	  in	  the	  clinic.	  As	  in	  our	  previous	  work,	  we	  used	  constant	  drug	  ratios	  to	  assess	  synergy.	  78,86,87	  	  That	  is,	  each	  drug	  in	  a	  condition	  was	  applied	  at	  its	  IC50	  value,	  or	  a	  fraction	  of	  the	  IC50	  value.	  For	  this	  set	  of	  experiments,	  eight	  concentrations	  were	  tested.	  Proliferation	  was	  assessed	  using	  an	  MTT	  assay,	  and	  the	  combination	  index	  (CI,	  a	  measure	  of	  the	  combined	  effect)	  was	  calculated	  using	  CalcuSyn	  software.	  Previous	  work	  in	  our	  lab	  demonstrated	  that	  a	  48-­‐hour	  drug	  exposure	  followed	  by	  a	  2-­‐hour	  MTT	  incubation	  was	  optimal	  for	  these	  assays	  with	  the	  invasive	  bladder	  cancer	  lines.	  78	  	  These	  conditions	  were	  maintained	  for	  all	  MTT	  assays	  described	  below.	  	  In	  the	  UMUC3	  cell	  line,	  the	  addition	  of	  emetine	  to	  the	  cisplatin-­‐gemcitabine	  therapy	  caused	  an	  additive	  decrease	  in	  cell	  proliferation,	  as	  demonstrated	  by	  a	  combination	  index	  between	  0.9-­‐1.1	  at	  all	  tested	  drug	  ratios.	  The	  most	  effective	  drug	  ratio	  resulted	  in	  a	  decrease	  in	  proliferation	  of	  28%	  +/-­‐	  2.6%	  between	  cells	  treated	  with	  emetine	  plus	  cisplatin-­‐gemcitabine	  and	  those	  treated	  with	  cisplatin-­‐gemcitabine	  alone	  (Figure	  6A).	  Similar	  results	  were	  found	  with	  the	  HT1376	  and	  T24	  cell	  lines	  where	  the	  addition	  of	  emetine	  further	  decreased	  cell	  proliferation	  by	  18%	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Figure	  6:	  Addition	  of	  Emetine	  to	  Cisplatin-­Gemcitabine	  Standard	  of	  Care	  
Therapy	  	  Cells	  were	  treated	  with	  drug	  alone	  or	  in	  combination	  at	  a	  constant	  ratio	  as	  indicated.	  Proliferation	  was	  analyzed	  via	  MTT	  assay.	  Data	  represent	  combined	  results	  from	  three	  independent	  experiments	  performed	  in	  quadruplicate.	  A)	  UMUC3	  cells,	  B)	  HT1376	  cells,	  C)	  T24	  cells	  
	  
Addition	  of	  Emetine	  to	  Carboplatin-­Gemcitabine	  Standard	  of	  Care	  Results	  in	  
an	  Additive	  Decrease	  in	  Cell	  Proliferation	  Next,	  we	  sought	  to	  examine	  the	  effect	  of	  adding	  emetine	  to	  carboplatin-­‐gemcitabine	  therapy,	  a	  common	  chemotherapy	  regimen	  given	  to	  patients	  that	  are	  clinically	  unfit	  to	  receive	  cisplatin.	  As	  with	  the	  previous	  set	  of	  experiments,	  we	  used	  a	  constant	  ratio	  of	  drugs	  based	  on	  their	  individual	  IC50	  values,	  again	  testing	  eight	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Figure	  7:	  Addition	  of	  Emetine	  to	  Carboplatin-­Gemcitabine	  Therapy	  	  Cells	  were	  treated	  with	  drug	  alone	  or	  in	  combination	  at	  a	  standard	  ratio	  24	  hours	  after	  plating.	  Proliferation	  assessed	  via	  MTT	  assay	  48	  hours	  after	  treatment.	  Data	  represent	  combined	  results	  from	  three	  independent	  experiments	  performed	  in	  quadruplicate.	  A)	  UMUC3	  cells,	  B)	  HT1376	  cells,	  C)	  T24	  cells.	  
	  
Low-­dose	  Emetine	  Decreases	  the	  Effective	  Cisplatin	  and	  Carboplatin	  Dose	  
Required	  to	  Inhibit	  Bladder	  Cancer	  Cell	  Proliferation	  Because	  emetine	  enhanced	  inhibition	  of	  bladder	  cancer	  cell	  proliferation	  by	  standard	  therapeutic	  regimens,	  we	  wondered	  if	  emetine	  could	  decrease	  the	  dose	  of	  cisplatin	  or	  carboplatin	  required	  to	  effectively	  inhibit	  proliferation.	  To	  answer	  this	  question,	  we	  used	  an	  MTT	  proliferation	  assay,	  but	  instead	  of	  using	  constant	  drug	  ratios,	  we	  treated	  with	  a	  fixed,	  low-­‐dose	  of	  emetine	  and	  gemcitabine,	  while	  decreasing	  the	  dose	  of	  cisplatin	  or	  carboplatin.	  We	  began	  with	  all	  the	  drugs	  at	  their	  calculated	  IC50,	  and	  then	  sequentially	  decreased	  the	  dose	  of	  cisplatin	  or	  carboplatin	  by	  10%	  until	  reaching	  zero.	  	  	  Strikingly,	  in	  the	  UMUC3	  cell	  line,	  when	  only	  0.68	  µM	  cisplatin	  was	  added	  to	  emetine	  (30	  nM)	  and	  gemcitabine	  (30	  nM),	  proliferation	  was	  blocked	  to	  the	  levels	  seen	  upon	  treatment	  with	  6.8µM	  cisplatin	  and	  30nM	  gemcitabine	  (figure	  8A).	  These	  results	  suggest	  that	  inclusion	  of	  nanomolar	  concentrations	  of	  emetine	  may	  allow	  a	  10-­‐fold	  reduction	  in	  the	  cisplatin	  dose	  while	  maintaining	  comparable	  anti-­‐proliferative	  effects,	  in	  vitro.	  The	  results	  were	  more	  modest	  with	  HT1376	  [figure	  8B,	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Figure	  8:	  Low	  Dose	  Emetine	  Reduces	  Effective	  Dose	  of	  Cisplatin	  Cells	  were	  treated	  with	  constant	  dose	  of	  gemcitabine	  with	  or	  without	  a	  constant	  dose	  of	  emetine	  in	  the	  presence	  of	  increasing	  concentrations	  of	  cisplatin.	  Data	  represent	  combined	  results	  from	  three	  independent	  experiments	  performed	  in	  quadruplicate.	  	  A)	  UMUC3	  cells,	  B)	  HT1376	  cells,	  C)	  T24	  cells	  	  	  
With	  respect	  to	  carboplatin,	  we	  also	  found	  that	  low	  dose	  emetine	  could	  reduce	  the	  dose	  of	  carboplatin	  required	  for	  anti-­‐proliferative	  effects.	  Again,	  we	  found	  30	  nM	  emetine	  resulted	  in	  a	  10-­‐fold	  decrease	  in	  the	  dose	  of	  carboplatin	  needed	  to	  block	  UMUC3	  cell	  proliferation	  seen	  with	  carboplatin	  and	  gemcitabine	  at	  IC50	  concentrations	  (Figure	  9A).	  Similar,	  albeit	  more	  modest,	  results	  were	  observed	  in	  HT1376	  [figure	  9B;	  4.4-­‐fold	  decrease	  in	  carboplatin	  (range:	  2-­‐6.7-­‐fold)].	  With	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Figure	  9:	  Low	  Dose	  Emetine	  Reduces	  Effective	  Dose	  of	  Carboplatin	  Cells	  were	  treated	  with	  constant	  dose	  of	  gemcitabine	  with	  or	  without	  a	  constant	  dose	  of	  emetine	  in	  the	  presence	  of	  increasing	  concentrations	  of	  carboplatin.	  Data	  represent	  combined	  results	  from	  three	  independent	  experiments	  performed	  in	  quadruplicate.	  A)	  UMUC3	  cells,	  B)	  HT1376	  cells,	  C)	  T24	  cells	  	  	  
Cisplatin-­Gemcitabine-­Emetine	  has	  a	  Greater	  Effect	  on	  Proliferation	  of	  
Invasive	  Bladder	  Cancer	  Cells	  than	  on	  Normal	  Bladder	  Epithelial	  When	  normal	  bladder	  epithelial	  cells	  were	  used	  in	  similar	  experiments,	  emetine	  had	  little	  or	  no	  additional	  affect	  on	  cell	  proliferation.	  The	  results	  were	  virtually	  identical	  in	  cells	  treated	  with	  increasing	  doses	  of	  cisplatin	  and	  a	  constant	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Figure	  10:	  Addition	  of	  Emetine	  does	  not	  Enhance	  Anti-­Proliferative	  Effect	  of	  
Normal	  Bladder	  Epithelial	  Cells	  Treated	  with	  Cisplatin-­Gemcitabine	  or	  
Carboplatin-­Gemcitabine.	  Normal	  bladder	  epithelial	  cells	  were	  treated	  with	  constant	  dose	  of	  gemcitabine	  with	  or	  without	  emetine	  in	  the	  presence	  of	  increasing	  doses	  of	  A)	  cisplatin	  or	  B)	  carboplatin.	  Data	  represent	  combined	  results	  from	  three	  independent	  experiments	  performed	  in	  quadruplicate.	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AIM	  1B:	  EXAMINE	  WHAT	  IS	  CAUSING	  THE	  DECREASE	  IN	  CELL	  PROLIFERATION	  
The	  Addition	  of	  Emetine	  to	  Cisplatin-­Gemcitabine	  Standard	  of	  Care	  Results	  in	  




Figure	  11:	  The	  Addition	  of	  Emetine	  to	  Cisplatin-­Gemcitabine	  Has	  Little	  to	  No	  
Effect	  on	  Apoptosis	  T24	  cells	  treated	  twice	  with	  drug	  alone	  or	  in	  combination	  (2	  µM	  cisplatin,	  9	  nM	  gemcitabine,	  30	  nM	  emetine),	  and	  collected	  for	  apoptosis	  analysis	  via	  ANNEXIN-­‐V-­‐FITC	  48	  hours	  after	  second	  treatment.	  Data	  is	  combined	  from	  2	  experiments	  	  

























Figure	  12:	  Effect	  of	  the	  Addition	  of	  Emetine	  to	  Cisplatin-­Gemcitabine	  on	  the	  
Cell	  Cycle	  T24	  cells	  treated	  with	  drug	  alone	  or	  in	  combination	  (2	  µM	  cisplatin,	  9	  nM	  gemcitabine,	  and	  30	  nM	  emetine)	  24	  hours	  after	  plating,	  and	  again	  72	  hours	  later.	  Collected	  for	  DNA-­‐PI	  analysis	  24	  hours	  after	  2nd	  treatment.	  
	  
Given	  the	  significant	  decrease	  in	  tumor	  cell	  proliferation,	  but	  lack	  of	  increase	  in	  apoptosis	  following	  emetine-­‐cisplatin-­‐gemcitabine	  treatment,	  the	  results	  suggest	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that	  the	  cells	  are	  either	  undergoing	  growth	  arrest	  or	  are	  dying	  via	  a	  mechanism	  other	  than	  apoptosis.	  
	  
The	  Addition	  of	  Emetine	  to	  Cisplatin-­Gemcitabine	  Results	  in	  a	  Modest	  Increase	  




Figure	  13:	  Emetine	  Modestly	  Increases	  Autophagy	  in	  Cisplatin-­Gemcitabine	  
Treated	  Bladder	  Cancer	  Cells	  UMUC3	  cells	  were	  treated	  for	  48	  hours	  with	  chemotherapeutic	  agents,	  labeled	  for	  1	  hour	  with	  MDC,	  and	  then	  analyzed	  by	  fluorescent	  microscopy	  immediately	  after	  mounting.	  Positive	  cells	  were	  counted	  in	  ImageJ	  as	  described	  in	  the	  materials	  and	  methods.	  Results	  represent	  combined	  data	  from	  two	  independent	  experiments.	  	  Eme	  =	  emetine,	  Cis	  =	  cisplatin,	  &	  Gem	  =	  gemcitabine.	  	  
	  
Cisplatin-­Gemcitabine-­Emetine	  Treatment	  May	  Permanently	  Growth	  Arrest	  
Bladder	  Cancer	  Cells	  
	   UMUC3	  cells	  were	  treated	  with	  30	  nM	  emetine,	  30	  nM	  gemcitabine	  and	  half	  and	  full	  IC50	  concentrations	  of	  cisplatin	  (3.4	  µM	  or	  6.8	  µM)	  or	  half	  and	  full	  IC50	  concentrations	  of	  carboplatin	  (36.5	  µM	  or	  73	  µM)	  for	  24	  or	  48	  hours.	  Cells	  were	  unable	  to	  recover	  when	  observed	  for	  14	  days	  post	  drug	  removal.	  Similar	  results	  were	  observed	  in	  T24	  cells.	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AIM	  2:	  EXAMINE	  THE	  MECHANISM	  BEHIND	  EMETINE’S	  ACTION	  




	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  14:	  Effect	  of	  Emetine	  on	  Global	  Protein	  Synthesis	  Western	  blot	  for	  biotin.	  UMUC3	  cells	  were	  treated	  as	  indicated	  for	  four	  hours	  during	  the	  metabolic	  labeling.	  Lane	  1:	  untreated,	  Lane	  2:	  30	  nM	  Emetine,	  and	  Lane	  3:	  untreated	  control	  sample	  not	  subjected	  to	  Click	  reaction	  with	  biotin-­‐labeled	  alkane	  	  
	  
Emetine	  Reduces	  Levels	  of	  Nuclear	  HIF-­1α 	  and	  HIF-­2α 	  but	  not	  HIF-­β 	  Previous	  studies	  by	  Gupta	  and	  colleagues	  demonstrated	  that	  100	  nM	  emetine	  significantly	  decreased	  HIF-­‐2α,	  but	  not	  HIF-­‐β	  expression	  in	  clear	  cell	  renal	  cell	  carcinoma	  cell	  lines.	  13	  	  To	  determine	  if	  emetine	  altered	  HIF	  protein	  expression	  in	  invasive	  bladder	  cancer	  cells,	  we	  treated	  UMUC3	  cells	  with	  increasing	  concentrations	  of	  emetine	  for	  4	  and	  24	  hours.	  Nuclear	  proteins	  were	  analyzed	  by	  western	  blot	  for	  HIF-­‐1α,	  HIF-­‐2α, and	  HIF-­‐1β.	  The	  results	  showed	  emetine	  rapidly	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Figure	  15:	  Emetine	  Reduces	  Nuclear	  HIF-­1α 	  and	  HIF-­2α 	  but	  not	  HIF-­
β  Expression	  A)	  UMUC3,	  B)	  HT1376,	  and	  C)	  T24	  cells	  treated	  with	  increasing	  concentrations	  of	  Emetine	  for	  4	  (A	  &	  B)	  and	  24	  (C)	  hours.	  Even	  quantities	  of	  protein	  were	  loaded	  onto	  SDS-­‐Page	  gel.	  Western	  blot	  for	  HIF-­‐1α,	  HIF-­‐2α,	  and	  HIF-­‐β	  proteins.	  Even	  protein	  loading	  was	  verified	  via	  Ponceau	  red	  stain	  and/or	  Lamin	  protein	  detection.	  	  	  
Low	  Dose	  Emetine	  Inhibits	  Synthesis	  of	  HIF-­1α 	  Taken	  together,	  our	  results	  suggest	  that	  low	  dose	  (30	  nM)	  emetine	  does	  not	  inhibit	  global	  protein	  synthesis	  in	  invasive	  bladder	  cancer	  cells,	  but	  instead	  appears	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DISCUSSION	  The	  standard	  of	  care	  for	  patients	  with	  muscle	  invasive	  bladder	  cancer	  consists	  of	  removal	  of	  the	  bladder	  and	  a	  chemotherapy	  regimen	  of	  cisplatin	  plus	  gemcitabine.	  46,48,91	  	  Unfortunately,	  bladder	  cancer	  is	  characterized	  by	  chemoresistance,	  and	  is	  only	  modestly	  responsive	  to	  this	  therapy.	  92	  	  Moreover,	  cisplatin	  is	  neurotoxic	  and	  nephrotoxic,	  limiting	  its	  use	  in	  patients.	  53	  	  As	  the	  median	  age	  of	  bladder	  cancer	  diagnosis	  is	  65,	  approximately	  50%	  of	  patients	  have	  co-­‐morbidities	  preventing	  them	  from	  receiving	  cisplatin.	  43	  	  These	  patients	  may	  be	  eligible	  to	  receive	  carboplatin	  and	  gemcitabine,	  an	  inferior	  chemotherapeutic	  regimen	  with	  less	  toxicity.	  With	  no	  comparable	  alternative,	  it	  is	  imperative	  to	  develop	  novel,	  effective	  therapies	  for	  these	  patients.	  	  In	  the	  current	  project,	  we	  set	  out	  to	  determine	  if	  the	  addition	  of	  emetine	  to	  the	  cisplatin-­‐gemcitabine	  or	  carboplatin-­‐gemcitabine	  therapy	  enhanced	  inhibition	  of	  bladder	  cancer	  cell	  proliferation	  and/or	  cell	  death.	  Using	  MTT	  proliferation	  assays,	  we	  found	  that	  addition	  of	  emetine	  to	  cisplatin-­‐gemcitabine	  treatment	  substantially	  decreased	  cell	  proliferation	  across	  a	  wide	  range	  of	  concentrations.	  Importantly,	  we	  demonstrated	  that	  addition	  of	  low	  dose,	  nanomolar	  concentrations	  of	  emetine	  allowed	  the	  effective	  dose	  of	  cisplatin	  or	  carboplatin	  to	  be	  reduced	  up	  to	  10-­‐fold.	  Given	  the	  significant	  toxicity	  of	  platinum-­‐based	  therapies,	  the	  ability	  to	  reduce	  the	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effective	  dose	  of	  these	  agents	  could	  allow	  patients	  previously	  deemed	  unfit	  for	  cisplatin	  or	  carboplatin	  to	  receive	  treatment.	  	  Previous	  work	  in	  our	  lab	  demonstrated	  that	  emetine	  acts	  synergistically	  with	  cisplatin	  to	  decrease	  bladder	  tumor	  cell	  proliferation.	  78	  	  We	  initially	  hypothesized	  that	  a	  similar	  synergistic	  response	  would	  occur	  upon	  the	  addition	  of	  emetine	  to	  the	  full	  standard	  of	  care	  regimen	  of	  cisplatin	  plus	  gemcitabine.	  Instead,	  the	  response	  was	  primarily	  additive	  with	  a	  few	  conditions	  showing	  slight	  synergy.	  Because	  gemcitabine	  is	  an	  anti-­‐proliferative	  drug,	  it	  is	  likely	  that	  the	  inclusion	  of	  gemcitabine	  reduced	  proliferation	  sufficiently	  that	  the	  effect	  of	  adding	  emetine	  was	  not	  as	  dramatic	  as	  in	  our	  initial	  work.	  Our	  previous	  studies	  also	  showed	  that	  emetine	  caused	  only	  a	  modest	  increase	  in	  apoptosis	  when	  added	  to	  cisplatin	  chemotherapy.	  78	  	  Similarly,	  the	  present	  studies	  show	  little	  to	  no	  increase	  in	  apoptosis	  with	  the	  emetine,	  cisplatin	  and	  gemcitabine	  combination.	  Because	  our	  cells	  look	  like	  they	  are	  injured	  and/or	  are	  dying	  under	  the	  microscope,	  (i.e.	  enlarged,	  granular	  and	  flattened),	  we	  explored	  whether	  the	  cells	  were	  dying	  from	  a	  mechanism	  other	  than	  apoptosis.	  	  	  Autophagy	  can	  be	  a	  pro-­‐survival	  response	  in	  a	  cell	  by	  degrading	  old	  or	  damaged	  components,	  or	  by	  re-­‐allocating	  its	  resources	  to	  a	  particular	  task.	  However,	  in	  certain	  cellular	  contexts	  autophagy	  can	  be	  a	  pro-­‐death	  response,	  particularly	  in	  cells	  that	  are	  apoptosis-­‐defective.	  93,94	  	  Other	  studies	  have	  demonstrated	  autophagy	  as	  a	  response	  in	  bladder	  cancer	  cells	  treated	  with	  cisplatin	  and	  or	  gemcitabine.	  90	  	  We	  demonstrate	  that	  autophagy	  is,	  at	  best,	  modestly	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increased	  upon	  the	  addition	  of	  emetine	  to	  cisplatin	  plus	  gemcitabine.	  If	  autophagic	  death	  were	  responsible	  for	  the	  observed	  decrease	  in	  cell	  proliferation,	  we	  would	  have	  expected	  to	  see	  a	  greater	  increase	  in	  the	  percentage	  of	  cells	  positive	  for	  autophagy.	  When	  cells	  were	  treated	  with	  the	  triple	  combination	  for	  24	  or	  48	  hours,	  they	  failed	  to	  proliferate	  upon	  drug	  removal.	  Therefore,	  autophagy	  is	  not	  acting	  as	  a	  pro-­‐survival	  mechanism	  in	  the	  cells	  under	  our	  experimental	  conditions.	  	  	  The	  triple	  drug	  therapy	  of	  emetine,	  cisplatin	  and	  gemcitabine,	  does	  not	  point	  to	  one	  particular	  mechanism	  as	  the	  cause	  behind	  the	  decrease	  in	  proliferation	  observed	  in	  muscle	  invasive	  bladder	  cancer	  cells.	  It	  is	  likely	  that	  up	  to	  50%	  of	  our	  cells	  are	  dying	  from	  apoptosis,	  25%	  are	  undergoing	  autophagy,	  and	  the	  remainder	  are	  either	  permanently	  growth	  arrested	  or	  senescent.	  	  Muscle	  invasive	  bladder	  cancer	  is	  associated	  with	  an	  increase	  in	  HIF-­‐α	  proteins	  expression.	  42	  	  HIF-­‐α	  proteins	  are	  transcription	  factors	  that	  induce	  transcription	  of	  genes	  involved	  in	  angiogenesis,	  glucose	  metabolism,	  proliferation,	  and	  migration,	  giving	  the	  cell	  a	  selective	  advantage.	  1,5	  	  In	  the	  three	  human	  muscle	  invasive	  bladder	  cancer	  cell	  lines	  used	  throughout	  this	  project,	  HIF-­‐α	  proteins	  are	  aberrantly	  expressed	  under	  normoxic	  conditions	  (personal	  communication,	  K	  Foreman,	  PhD).	  As	  emetine	  has	  been	  previously	  shown	  to	  decrease	  HIF-­‐2α	  expression	  in	  clear	  cell	  renal	  cell	  carcinoma	  cell	  lines	  13	  ,	  we	  examined	  if	  emetine	  altered	  hypoxia	  signaling	  in	  order	  to	  decrease	  muscle	  invasive	  bladder	  cancer	  cell	  proliferation.	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Treatment	  of	  cells	  in	  culture	  with	  nanomolar	  levels	  of	  emetine	  preferentially	  reduced	  levels	  of	  HIF-­‐1α	  and	  HIF-­‐2α,	  but	  not	  HIF-­‐β proteins.	  This	  effectively	  reduced	  the	  transcription	  of	  their	  response	  genes,	  likely	  decreasing	  the	  cell’s	  selective	  advantage,	  and	  leading	  to	  a	  decrease	  in	  proliferation.	  Emetine’s	  precise	  regulation	  of	  the	  HIF-­‐α	  subunit	  suggests	  a	  potential	  therapeutic	  role	  in	  cancers	  where	  HIF-­‐α	  proteins	  are	  upregulated,	  such	  as	  muscle	  invasive	  bladder	  cancer.	  Since	  HIF-­‐α	  proteins	  are	  not	  upregulated	  to	  the	  same	  extent	  in	  non-­‐muscle	  invasive	  bladder	  cancer	  cells,	  it	  is	  unlikely	  that	  emetine	  would	  be	  as	  effective	  in	  these	  tumors.	  
In	  vivo	  work	  is	  necessary	  to	  supplement	  these	  results,	  and	  is	  currently	  being	  pursued	  by	  our	  lab.	  Preliminary	  studies	  show	  that	  emetine-­‐cisplatin-­‐gemcitabine	  treatment	  significantly	  inhibits	  tumor	  growth	  compared	  to	  cisplatin-­‐gemcitabine	  treatment	  in	  a	  subcutaneous	  tumor	  model	  of	  invasive	  bladder	  cancer	  (personal	  communication,	  K	  Foreman,	  PhD).	  Orthotopic	  models	  of	  bladder	  cancer	  need	  to	  be	  studied	  next	  before	  possible	  clinical	  trials	  can	  be	  initiated.	  Results	  from	  this	  work	  will	  be	  telling	  in	  our	  hopes	  of	  clinically	  testing	  the	  effectiveness	  of	  the	  triple	  therapy	  in	  patients	  suffering	  from	  invasive	  bladder	  cancer.	  	  Additional	  clinical	  studies	  are	  necessary	  to	  assess	  emetine’s	  toxicity	  as	  part	  of	  the	  proposed	  therapy.	  Emetine	  has	  been	  examined	  as	  part	  of	  a	  combination	  therapy	  with	  cyclophosphamide	  in	  1	  trial	  of	  6	  lung	  cancer	  patients,	  where	  the	  investigator	  noted	  a	  definite	  response	  in	  all	  6	  patients.	  75	  	  This	  study,	  as	  well	  as	  those	  examining	  emetine	  as	  a	  single-­‐agent,	  cite	  cardiotoxicity	  and	  muscle	  weakness	  as	  
63	  
	  	  
dose-­‐limiting	  considerations	  in	  the	  administration	  of	  emetine.	  70,72,75	  	  Mastrangelo	  reports	  the	  absence	  of	  these	  toxicities	  when	  administering	  emetine	  at	  1mg/kg	  daily	  for	  10	  days.	  71	  	  In	  order	  to	  relate	  doses	  used	  in	  our	  tissue	  culture	  studies	  to	  those	  used	  in	  clinical	  trials,	  our	  lab	  has	  previously	  calculated	  that	  a	  70	  kg	  individual	  would	  have	  received	  3,000	  nM	  emetine	  in	  a	  1	  mg	  dose.	  78	  	  While	  it	  is	  difficult	  to	  directly	  compare	  treating	  a	  tissue	  culture	  monolayer	  with	  treating	  a	  tumor	  in	  a	  patient,	  our	  results	  suggest	  a	  smaller	  effective	  dose	  than	  what	  has	  previously	  been	  demonstrated	  to	  be	  free	  of	  toxic	  side	  effects.	  	  In	  conclusion,	  our	  results	  suggest	  that	  the	  inclusion	  of	  a	  low	  dose	  of	  emetine	  to	  the	  cisplatin-­‐gemcitabine	  or	  carboplatin-­‐gemcitabine	  standard	  of	  care	  allow	  for	  up	  to	  a	  10-­‐fold	  reduction	  in	  effect	  dose	  of	  cisplatin	  or	  carboplatin.	  This	  is	  important,	  as	  the	  toxicity	  of	  these	  drugs	  limit	  the	  number	  of	  patients	  able	  to	  undergo	  chemotherapy.	  Moreover,	  we	  predict	  that	  the	  effective	  dose	  of	  emetine	  will	  not	  be	  accompanied	  with	  toxic	  side	  effects	  of	  its	  own.	  Additionally,	  our	  results	  suggest	  that	  emetine	  acts	  to	  regulate	  hypoxia	  signaling	  in	  invasive	  bladder	  cancer	  cells	  by	  decreasing	  protein	  synthesis	  of	  the	  HIF-­‐α	  subunit.	  This	  may	  effectively	  reduce	  the	  tumor	  cell’s	  selective	  advantage	  and	  proliferative	  potential.
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